• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利那洛肽或其他药物治疗 IBS-C 或 CIC 患者的粪便稠度对肠道运动满意度的影响:CONTOR 研究的真实世界证据。

The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study.

机构信息

Ironwood Pharmaceuticals Inc., Cambridge, MA.

Allergan plc, Madison, NJ.

出版信息

J Clin Gastroenterol. 2019 Nov/Dec;53(10):737-743. doi: 10.1097/MCG.0000000000001245.

DOI:10.1097/MCG.0000000000001245
PMID:31361710
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6791496/
Abstract

GOALS

This study aimed to characterize the impact of stool consistency on patient-reported bowel movement (BM) satisfaction in patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation, with a focus on linaclotide.

BACKGROUND

As new medications for constipation become available, understanding patients' perceptions of treatment effects may help clinicians manage patient expectations and inform clinical decision-making.

MATERIALS AND METHODS

Data were derived from the Chronic Constipation and IBS-C Treatment and Outcomes Real-world Research Platform (CONTOR) study from 2 patient-reported 7-day daily BM diaries to create a dataset of 2922 diaries representing 26,524 BMs for 1806 participants. Binary variables were created for: medication(s) used in the past 24 hours and categorization of BMs as loose or watery stools (LoWS), hard or lumpy stools (HoLS), or intermediate (neither LoWS nor HoLS). The relationship between stool consistency, medication use, and BM satisfaction was analyzed using logistic regression with SEs corrected for repeated observations.

RESULTS

BMs characterized as intermediate stools and LoWS were satisfactory more often (61.2% and 51.2%, respectively) than HoLS (19.4%). Participants who reported taking linaclotide rated a similar proportion of BMs as satisfactory when described as LoWS (65.6%) or intermediate (64.1%). Linaclotide use was associated with higher odds of BMs being reported as satisfactory compared with nonlinaclotide use (odds ratio: 1.23, P<0.05).

CONCLUSIONS

Overall, CONTOR participants were more likely to report BMs classified as LoWS or intermediate as satisfactory, versus HoLS. Participants taking linaclotide were more likely to be satisfied, particularly those reporting LoWS, versus those not taking linaclotide.

摘要

目的

本研究旨在描述粪便稠度对肠易激综合征便秘型(IBS-C)或慢性特发性便秘患者报告的排便(BM)满意度的影响,重点关注利那洛肽。

背景

随着新的便秘治疗药物的出现,了解患者对治疗效果的看法可能有助于临床医生管理患者的期望并为临床决策提供信息。

材料和方法

数据来自慢性便秘和 IBS-C 治疗及结局真实世界研究平台(CONTOR)研究,该研究使用患者报告的 2 个为期 7 天的每日 BM 日记,创建了一个包含 1806 名参与者的 2922 个 BM 日记的数据集,共 26524 个 BM。创建了两个二项变量:过去 24 小时使用的药物和粪便分类为稀便(LoWS)或水样便(HoLS)、硬便或块状便(HoLS)或中间便(既非 LoWS 也非 HoLS)。使用具有重复观察校正的 SE 的逻辑回归分析粪便稠度、药物使用与 BM 满意度之间的关系。

结果

描述为中间便和 LoWS 的 BM 更常被认为是满意的(分别为 61.2%和 51.2%),而 HoLS 仅为 19.4%。报告服用利那洛肽的参与者将 LoWS(65.6%)或中间便(64.1%)描述为满意的 BM 比例相似。与非利那洛肽使用者相比,利那洛肽使用者报告的 BM 更有可能被认为是满意的(比值比:1.23,P<0.05)。

结论

总体而言,CONTOR 参与者更有可能报告 LoWS 或中间便分类的 BM 为满意,而不是 HoLS。服用利那洛肽的参与者更有可能感到满意,特别是报告 LoWS 的参与者,而不是未服用利那洛肽的参与者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36f2/6791496/f83c49d5830b/mcg-53-737-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36f2/6791496/8d1e1f9d33e1/mcg-53-737-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36f2/6791496/f83c49d5830b/mcg-53-737-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36f2/6791496/8d1e1f9d33e1/mcg-53-737-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36f2/6791496/f83c49d5830b/mcg-53-737-g005.jpg

相似文献

1
The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study.利那洛肽或其他药物治疗 IBS-C 或 CIC 患者的粪便稠度对肠道运动满意度的影响:CONTOR 研究的真实世界证据。
J Clin Gastroenterol. 2019 Nov/Dec;53(10):737-743. doi: 10.1097/MCG.0000000000001245.
2
Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.鸟苷酸环化酶 C 激动剂治疗便秘型肠易激综合征和慢性特发性便秘的疗效和耐受性:系统评价和荟萃分析。
Am J Gastroenterol. 2018 Mar;113(3):329-338. doi: 10.1038/ajg.2017.495. Epub 2018 Jan 30.
3
Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.确定利那洛肽在日本便秘型肠易激综合征患者中的最佳剂量:一项 II 期随机、双盲、安慰剂对照研究。
Neurogastroenterol Motil. 2018 May;30(5):e13275. doi: 10.1111/nmo.13275. Epub 2017 Dec 26.
4
IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment.IBS 患者的粪便常呈现稀便与硬便/团块便之间的频繁波动:对治疗的启示。
Am J Gastroenterol. 2012 Feb;107(2):286-95. doi: 10.1038/ajg.2011.358. Epub 2011 Nov 8.
5
Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).使用确定性链接的行政索赔和患者报告数据对便秘型肠易激综合征和慢性特发性便秘患者进行综合评估:慢性便秘和肠易激综合征 C 型治疗和结局真实世界研究平台(CONTOR)。
J Med Econ. 2020 Oct;23(10):1072-1083. doi: 10.1080/13696998.2020.1799816. Epub 2020 Aug 11.
6
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.低剂量利那洛肽(72μg)治疗慢性特发性便秘:一项为期 12 周、随机、双盲、安慰剂对照试验。
Am J Gastroenterol. 2018 Jan;113(1):105-114. doi: 10.1038/ajg.2017.230. Epub 2017 Aug 22.
7
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.Linaclotide 治疗便秘型肠易激综合征的 3 期随机临床试验:中国及其他地区研究结果
J Gastroenterol Hepatol. 2018 May;33(5):980-989. doi: 10.1111/jgh.14086. Epub 2018 Mar 12.
8
Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis.利那洛肽治疗慢性特发性便秘和便秘型肠易激综合征的安全性和耐受性:汇总的 3 期分析。
Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):397-406. doi: 10.1080/17474124.2019.1575203. Epub 2019 Feb 18.
9
Episodic nature of symptoms in irritable bowel syndrome.肠易激综合征症状的发作性特征。
Am J Gastroenterol. 2014 Sep;109(9):1450-60. doi: 10.1038/ajg.2014.181. Epub 2014 Jul 1.
10
Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation.利那洛肽可增加盲肠 pH 值、加速结肠传输并增加便秘型肠易激综合征患者的结肠蠕动。
Neurogastroenterol Motil. 2019 Feb;31(2):e13492. doi: 10.1111/nmo.13492. Epub 2018 Oct 23.

引用本文的文献

1
Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation.加氏乳杆菌345A在慢性便秘中的治疗价值
Neurogastroenterol Motil. 2025 May;37(5):e70012. doi: 10.1111/nmo.70012. Epub 2025 Mar 3.
2
The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review.利那洛肽在儿童功能性便秘或肠易激综合征中的应用:回顾性图表分析。
Paediatr Drugs. 2021 May;23(3):307-314. doi: 10.1007/s40272-021-00444-4. Epub 2021 Apr 20.

本文引用的文献

1
What Is New in Rome IV.罗马IV中有哪些新内容。
J Neurogastroenterol Motil. 2017 Apr 30;23(2):151-163. doi: 10.5056/jnm16214.
2
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.优化利那洛肽在便秘型肠易激综合征患者中的应用:专家共识报告
Adv Ther. 2017 Mar;34(3):587-598. doi: 10.1007/s12325-016-0473-8. Epub 2017 Jan 12.
3
Bowel Disorders.肠道疾病
Gastroenterology. 2016 Feb 18. doi: 10.1053/j.gastro.2016.02.031.
4
The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden.以便秘为主的肠易激综合征和慢性特发性便秘的范围:美国评估症状、就医情况和疾病负担的调查
Am J Gastroenterol. 2015 Apr;110(4):580-7. doi: 10.1038/ajg.2015.67. Epub 2015 Mar 17.
5
Factors affecting satisfaction with treatment in European women with chronic constipation: An internet survey.影响欧洲慢性便秘女性治疗满意度的因素:一项网络调查。
United European Gastroenterol J. 2013 Oct;1(5):375-84. doi: 10.1177/2050640613494200.
6
Levels of satisfaction with current chronic constipation treatment options in Europe - an internet survey.欧洲对当前慢性便秘治疗选择的满意度水平——一项互联网调查。
Aliment Pharmacol Ther. 2013 Jan;37(1):137-45. doi: 10.1111/apt.12124. Epub 2012 Nov 5.
7
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.Linaclotide 治疗便秘型肠易激综合征的 26 周随机、双盲、安慰剂对照试验:评估疗效和安全性。
Am J Gastroenterol. 2012 Nov;107(11):1702-12. doi: 10.1038/ajg.2012.254.
8
Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome.与便秘主导的肠易激综合征相关的健康相关生活质量、工作生产力和医疗保健资源的利用。
Curr Med Res Opin. 2011 Nov;27(11):2213-22. doi: 10.1185/03007995.2011.623157. Epub 2011 Sep 28.
9
Systematic review: impact of constipation on quality of life in adults and children.系统评价:便秘对成人和儿童生活质量的影响。
Aliment Pharmacol Ther. 2010 May;31(9):938-49. doi: 10.1111/j.1365-2036.2010.04273.x. Epub 2010 Feb 20.
10
Risk factors for chronic constipation and a possible role of analgesics.慢性便秘的风险因素及镇痛药的潜在作用。
Neurogastroenterol Motil. 2007 Nov;19(11):905-11. doi: 10.1111/j.1365-2982.2007.00974.x.